Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Retained Earnings
kr19.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Retained Earnings
kr856.8m
CAGR 3-Years
14%
CAGR 5-Years
14%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Retained Earnings
-kr946m
CAGR 3-Years
11%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Retained Earnings
-kr434m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Probi AB
STO:PROB
Retained Earnings
kr608.3m
CAGR 3-Years
-19%
CAGR 5-Years
-9%
CAGR 10-Years
16%
BioArctic AB
STO:BIOA B
Retained Earnings
kr1B
CAGR 3-Years
23%
CAGR 5-Years
13%
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Retained Earnings?
Retained Earnings
19.8B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Retained Earnings amounts to 19.8B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Retained Earnings growth rate?
Retained Earnings CAGR 1Y
9%

Over the last year, the Retained Earnings growth was 9%.

Back to Top